FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis
| Autor: | Patrick K A Kearns, Sarah J Martin, Jessie Chang, Rozanna Meijboom, Elizabeth N York, Yingdi Chen, Christine Weaver, Amy Stenson, Katarzyna Hafezi, Stacey Thomson, Elizabeth Freyer, Lee Murphy, Adil Harroud, Peter Foley, David Hunt, Margaret McLeod, Jonathon O'Riordan, F J Carod-Artal, Niall J J MacDougall, Sergio E Baranzini, Adam D Waldman, Peter Connick, Siddharthan Chandran |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Multiple Sclerosis Clinical Sciences Relapsing-Remitting Neurodegenerative Autoimmune Disease Cohort Studies Multiple Sclerosis Relapsing-Remitting Clinical Research neuroradiology Humans Prospective Studies neurogenetics screening and diagnosis Other Medical and Health Sciences neurology Neurosciences General Medicine Brain Disorders internal medicine Detection Good Health and Well Being Neurological Public Health and Health Services Disease Progression epidemiology Biomarkers 4.2 Evaluation of markers and technologies |
| Zdroj: | BMJ open, vol 12, iss 6 Kearns, P K A, Martin, S J, Chang, J, Meijboom, R, York, E N, Chen, Y, Weaver, C, Stenson, A, Hafezi, K, Thomson, S, Freyer, E, Murphy, L, Harroud, A, Foley, P, Hunt, D, Mcleod, M, O'riordan, J, Carod-artal, F J, Macdougall, N J J, Baranzini, S E, Waldman, A D, Connick, P & Chandran, S 2022, ' FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis ', BMJ Open, vol. 12, no. 6, pp. e058506 . https://doi.org/10.1136/bmjopen-2021-058506 |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2021-058506 |
| Popis: | PurposeMultiple sclerosis (MS) is an immune-mediated, neuroinflammatory disease of the central nervous system and in industrialised countries is the most common cause of progressive neurological disability in working age persons. While treatable, there is substantial interindividual heterogeneity in disease activity and response to treatment. Currently, the ability to predict at diagnosis who will have a benign, intermediate or aggressive disease course is very limited. There is, therefore, a need for integrated predictive tools to inform individualised treatment decision making.ParticipantsEstablished with the aim of addressing this need for individualised predictive tools, FutureMS is a nationally representative, prospective observational cohort study of 440 adults with a new diagnosis of relapsing-remitting MS living in Scotland at the time of diagnosis between May 2016 and March 2019.Findings to dateThe study aims to explore the pathobiology and determinants of disease heterogeneity in MS and combines detailed clinical phenotyping with imaging, genetic and biomarker metrics of disease activity and progression. Recruitment, baseline assessment and follow-up at year 1 is complete. Here, we describe the cohort design and present a profile of the participants at baseline and 1 year of follow-up.Future plansA third follow-up wave for the cohort has recently begun at 5 years after first visit and a further wave of follow-up is funded for year 10. Longer-term follow-up is anticipated thereafter. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|